Delta variant of coronavirus could evade immune system, finds research

The human immune system can’t produce the defence molecules against the Delta variant as effectively as against the other variants of coronavirus, revealed a study.

Dr. Krishnan Harshan’s group led the study, in collaboration with Dr. Divya Tej Sowpati’s group at CSIR-Centre for Cellular and Molecular Biology, to try to understand if hosts, that is humans infected by the virus, react differently to the different SARS-CoV-2 variants.

In this study published in Microbiology Spectrum journal, the researchers found that the immune system could not produce the defence molecules against the Delta variant as effectively as the other variants. While infection due to the other four variants alerted the immune system quickly, the Delta variant could silently replicate in the host cells.

In the last almost three years, there have been many SARS-CoV-2 variants spreading across the world. Their outcomes have varied greatly, with the Delta variant being the deadliest.

The researchers selected five different SARS-CoV-2 variants and studied how the human immune system responds to the variants. The studied variants included Alpha, Delta, and three other variants that emerged before the Alpha variant. Upon viral infection, the first line of attack by the host’s immune system is by producing certain defence chemicals that break down the viruses. The researchers studied how their production responds to these five variants.

“We infected the human cells in a cell culture system with these different variants of the virus and monitored the production of known immune defence molecules and the activation of signaling pathways associated with them,” said Dixit Tandel, the first author of the study.

“We navigated through the hundreds of immune pathways known to us using high throughput sequencing and analysis,” said Dr. Nitesh Kumar Singh, who worked on the project with Dr Sowpati.

“We have identified that molecular mechanisms regulating the host immune response have not been as potent against the Delta variant of SARS-CoV-2. This also includes the production of interferons, immune molecules often used for antiviral therapies. The study hints at why the Delta variant could spread more easily,” said Dr. Krishnan Harshan, the lead investigator in this work.

He added that the study also helps us understand how viruses evolve with changing effects on human hosts.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 12 2022. 20: 24 IST